---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-239098"
form_type: "8-K"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2023-09-21T23:59:59+00:00"
generated_at: "2026-06-10T10:33:23.166169+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Travere's FILSPARI misses eGFR total slope endpoint but achieves chronic slope significance in IgAN

## Summary
- eGFR total slope difference vs irbesartan 1.0 mL/min/1.73m2 per year, p=0.058 (missed statistical significance).
- eGFR chronic slope difference 1.1 mL/min/1.73m2 per year, p=0.037 (statistically significant).
- Company to submit sNDA for full FDA approval of FILSPARI in IgAN in first half of 2024.
- EU CMA decision for sparsentan in IgAN expected from CHMP around end of 2023.

## SEC filing metadata
- accession: 0001193125-23-239098
- form_type: 8-K
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2023-09-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000119312523239098/0001193125-23-239098-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000119312523239098/d530177d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-239098
- JSON: https://secwatch.observer/filing/0001193125-23-239098.json
- Plain text: https://secwatch.observer/filing/0001193125-23-239098.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.